[시장보고서]RS 바이러스 백신 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

RS 바이러스 백신 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

Respiratory Syncytial Virus Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

상품코드 : 1742555

리서치사 : Transparency Market Research

발행일 : 2025년 04월

페이지 정보 : 영문 175 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,030,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,188,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 16,345,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

RS 바이러스 백신 시장 - 조사 범위

TMR의 조사 보고서 "세계 RS 바이러스 백신 시장"은 2025-2035년 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 있습니다. 이 보고서는 2019년부터 2035년까지의 세계 RS 바이러스 백신 시장의 수익과 예측을 제공하고자 2025년을 기준 연도로, 2035년을 예측 연도로 설정했습니다. 또한, 2025-2035년까지의 세계 RS 바이러스 백신 시장의 복합 연간 성장률(CAGR %)을 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참고하여 RS 바이러스 백신 시장을 이해하고자 했습니다.

시장 현황
2024년 시장 규모	37억 달러
2035년 시장 규모	159억 달러
CAGR	13.8%

이 보고서는 세계 RS 바이러스 백신 시장의 경쟁 환경을 조사하고 있습니다. 세계 RS 바이러스 백신 시장에서 사업을 전개하는 주요 기업이 확인되었으며, 각 기업은 다양한 속성별로 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향, SWOT는 세계 RS 바이러스 백신 시장 기업의 속성이며, 이 보고서에서 소개합니다.

시장 기업 - 경쟁 매트릭스(기업 계층별·규모별)
시장 점유율 분석 기업별(2024년)
기업 개요
- GSK plc
- Moderna, Inc.
- Pfizer, Inc.
- Sanofi
- AstraZeneca
- MAXVAX Biotechnology Limited
- Guangzhou Patronus Biotech Co., Ltd.
- Sinocelltech Ltd.
- Shenzhen Shenxin Biotechnology Co., Ltd
- Starna Therapeutics
- Blue Lake Biotechnology Inc.

KSM

영문 목차

영문목차

Respiratory Syncytial Virus Vaccine Market - Scope of Report

TMR's report on the global respiratory syncytial virus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global respiratory syncytial virus vaccine market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global respiratory syncytial virus vaccine market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the respiratory syncytial virus vaccine market.

Market Snapshot
Market Value in 2024	US$ 3.7 Bn
Market Value in 2035	US$ 15.9 Bn
CAGR	13.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global respiratory syncytial virus vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global respiratory syncytial virus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory syncytial virus vaccine market.

The report delves into the competitive landscape of the global respiratory syncytial virus vaccine market. Key players operating in the global respiratory syncytial virus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory syncytial virus vaccine market profiled in this report.

Key Questions Answered in global respiratory syncytial virus vaccine Market Report:

What is the sales/revenue generated by respiratory syncytial virus vaccine across all regions during the forecast period?
What are the opportunities in the global respiratory syncytial virus vaccine market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Respiratory Syncytial Virus Vaccine Market - Research Objectives and Research Approach

The comprehensive report on the global respiratory syncytial virus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory syncytial virus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory syncytial virus vaccine market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Respiratory Syncytial Virus Vaccine Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, 2020-2035
- 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Healthcare Expenditure Data Across Key Countries
5.2. Technological Advancements
5.3. Regulatory Scenario across Key Regions / Countries
5.4. PORTER's Five Forces Analysis
5.5. PESTEL Analysis
5.6. Key Industry Events

6. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Vaccine Type

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Vaccine Type, 2020-2035
- 6.3.1. Recombinant/Subunit Vaccines
- 6.3.2. mAB Injection
- 6.3.3. mRVaccines
- 6.3.4. Others
6.4. Market Attractiveness By Vaccine Type

7. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Age Group

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Age Group, 2020-2035
- 7.3.1. Adults & Geriatrics
- 7.3.2. Children & Pregnant Mothers
7.4. Market Attractiveness By Age Group

8. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Sales Channel

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Sales Channel, 2020-2035
- 8.3.1. Retail Pharmacies
- 8.3.2. Hospital Pharmacies
- 8.3.3. Others
8.4. Market Attractiveness By Sales Channel

9. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Region

9.1. Key Findings
9.2. Market Value Forecast By Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness By Region

10. North America Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast By Vaccine Type, 2020-2035
- 10.2.1. Recombinant/Subunit Vaccines
- 10.2.2. mAB Injection
- 10.2.3. mRVaccines
- 10.2.4. Others
10.3. Market Value Forecast By Age Group, 2020-2035
- 10.3.1. Adults & Geriatrics
- 10.3.2. Children & Pregnant Mothers
10.4. Market Value Forecast By Sales Channel, 2020-2035
- 10.4.1. Retail Pharmacies
- 10.4.2. Hospital Pharmacies
- 10.4.3. Others
10.5. Market Value Forecast By Country, 2020-2035
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Vaccine Type
- 10.6.2. By Age Group
- 10.6.3. By Sales Channel
- 10.6.4. By Country

11. Europe Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast By Vaccine Type, 2020-2035
- 11.2.1. Recombinant/Subunit Vaccines
- 11.2.2. mAB Injection
- 11.2.3. mRVaccines
- 11.2.4. Others
11.3. Market Value Forecast By Age Group, 2020-2035
- 11.3.1. Adults & Geriatrics
- 11.3.2. Children & Pregnant Mothers
11.4. Market Value Forecast By Sales Channel, 2020-2035
- 11.4.1. Retail Pharmacies
- 11.4.2. Hospital Pharmacies
- 11.4.3. Others
11.5. Market Value Forecast By Country / Sub-region, 2020-2035
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Spain
- 11.5.5. Italy
- 11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
- 11.6.1. By Vaccine Type
- 11.6.2. By Age Group
- 11.6.3. By Sales Channel
- 11.6.4. By Country / Sub-region

12. Asia Pacific Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast By Vaccine Type, 2020-2035
- 12.2.1. Recombinant/Subunit Vaccines
- 12.2.2. mAB Injection
- 12.2.3. mRVaccines
- 12.2.4. Others
12.3. Market Value Forecast By Age Group, 2020-2035
- 12.3.1. Adults & Geriatrics
- 12.3.2. Children & Pregnant Mothers
12.4. Market Value Forecast By Sales Channel, 2020-2035
- 12.4.1. Retail Pharmacies
- 12.4.2. Hospital Pharmacies
- 12.4.3. Others
12.5. Market Value Forecast By Country / Sub-region, 2020-2035
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
- 12.6.1. By Vaccine Type
- 12.6.2. By Age Group
- 12.6.3. By Sales Channel
- 12.6.4. By Country / Sub-region

13. Latin America Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast By Vaccine Type, 2020-2035
- 13.2.1. Recombinant/Subunit Vaccines
- 13.2.2. mAB Injection
- 13.2.3. mRVaccines
- 13.2.4. Others
13.3. Market Value Forecast By Age Group, 2020-2035
- 13.3.1. Adults & Geriatrics
- 13.3.2. Children & Pregnant Mothers
13.4. Market Value Forecast By Sales Channel, 2020-2035
- 13.4.1. Retail Pharmacies
- 13.4.2. Hospital Pharmacies
- 13.4.3. Others
13.5. Market Value Forecast By Country / Sub-region, 2020-2035
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
- 13.6.1. By Vaccine Type
- 13.6.2. By Age Group
- 13.6.3. By Sales Channel
- 13.6.4. By Country / Sub-region

14. Middle East & Africa Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast By Vaccine Type, 2020-2035
- 14.2.1. Recombinant/Subunit Vaccines
- 14.2.2. mAB Injection
- 14.2.3. mRVaccines
- 14.2.4. Others
14.3. Market Value Forecast By Age Group, 2020-2035
- 14.3.1. Adults & Geriatrics
- 14.3.2. Children & Pregnant Mothers
14.4. Market Value Forecast By Sales Channel, 2020-2035
- 14.4.1. Retail Pharmacies
- 14.4.2. Hospital Pharmacies
- 14.4.3. Others
14.5. Market Value Forecast By Country / Sub-region, 2020-2035
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
- 14.6.1. By Vaccine Type
- 14.6.2. By Age Group
- 14.6.3. By Sales Channel
- 14.6.4. By Country / Sub-region

15. Competition Landscape

15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2024)
15.3. Company Profiles
- 15.3.1. GSK plc
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Financial Overview
  - 15.3.1.3. Product Portfolio
  - 15.3.1.4. Business Strategies
  - 15.3.1.5. Recent Developments
- 15.3.2. Moderna, Inc.
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Financial Overview
  - 15.3.2.3. Product Portfolio
  - 15.3.2.4. Business Strategies
  - 15.3.2.5. Recent Developments
- 15.3.3. Pfizer, Inc.
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Financial Overview
  - 15.3.3.3. Product Portfolio
  - 15.3.3.4. Business Strategies
  - 15.3.3.5. Recent Developments
- 15.3.4. Sanofi
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Financial Overview
  - 15.3.4.3. Product Portfolio
  - 15.3.4.4. Business Strategies
  - 15.3.4.5. Recent Developments
- 15.3.5. AstraZeneca
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Financial Overview
  - 15.3.5.3. Product Portfolio
  - 15.3.5.4. Business Strategies
  - 15.3.5.5. Recent Developments
- 15.3.6. MAXVAX Biotechnology Limited
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Financial Overview
  - 15.3.6.3. Product Portfolio
  - 15.3.6.4. Business Strategies
  - 15.3.6.5. Recent Developments
- 15.3.7. Guangzhou Patronus Biotech Co., Ltd.
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Financial Overview
  - 15.3.7.3. Product Portfolio
  - 15.3.7.4. Business Strategies
  - 15.3.7.5. Recent Developments
- 15.3.8. Sinocelltech Ltd.
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Financial Overview
  - 15.3.8.3. Product Portfolio
  - 15.3.8.4. Business Strategies
  - 15.3.8.5. Recent Developments
- 15.3.9. Shenzhen Shenxin Biotechnology Co., Ltd
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Financial Overview
  - 15.3.9.3. Product Portfolio
  - 15.3.9.4. Business Strategies
  - 15.3.9.5. Recent Developments
- 15.3.10. Starna Therapeutics
  - 15.3.10.1. Company Overview
  - 15.3.10.2. Financial Overview
  - 15.3.10.3. Product Portfolio
  - 15.3.10.4. Business Strategies
  - 15.3.10.5. Recent Developments
- 15.3.11. Blue Lake Biotechnology Inc.
  - 15.3.11.1. Company Overview
  - 15.3.11.2. Financial Overview
  - 15.3.11.3. Product Portfolio
  - 15.3.11.4. Business Strategies
  - 15.3.11.5. Recent Developments

한글목차

RS 바이러스 백신 시장 - 조사 범위

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약

제4장 시장 개요

제5장 주요 인사이트

제6장 세계의 시장 분석과 예측 : 백신 종류별

제7장 세계의 시장 분석과 예측 : 연령층별

제8장 세계의 시장 분석과 예측 : 판매 채널별

제9장 세계의 시장 분석과 예측 : 지역별

제10장 북미의 시장 분석과 예측

제11장 유럽의 시장 분석과 예측

제12장 아시아태평양의 시장 분석과 예측

제13장 라틴아메리카의 시장 분석과 예측

제14장 중동 및 아프리카의 시장 분석과 예측

제15장 경쟁 구도